Magnetic-silica based nucleic acid extraction for Human Immunodeficiency Virus Type-1 drug-resistance testing in low viremic patients

Journal of Clinical Virology

Volumn 47, Issue 1, 2010, Pages 8-12

  Milia, Maria Grazia ^a   Allice, Tizano ^a   Gregori, Gabriella ^a   Mussino, Stefano ^a   Orofino, Giancarlo ^a   Bonora, Stefano ^a   Ghisetti, Valeria ^a  

^a AMEDEO DI SAVOIA HOSPITAL   (Italy)

Author keywords

Direct full population sequencing; Drug resistance; Genotypic test; HIV 1; Human Immunodeficiency Virus Type 1; NeM; NNRTI; non nucleoside reverse transcriptase inhibitor; NRTI; Nucleic acid extraction; nucleoside reverse transcriptase inhibitor; NucliSENS easyMAG; P; PCR; PI; polymerase chain reaction; protease; protease inhibitor; reverse transcriptase; RT

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SILICON DIOXIDE; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAGNETISM; MAJOR CLINICAL STUDY; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; RNA EXTRACTION; STANDARD; VIREMIA;

ANTI-HIV AGENTS; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MAGNETICS; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; SILICON DIOXIDE; VIRAL LOAD; VIREMIA;

EID: 72049127229     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.10.012     Document Type: Article

References (28)

1. Hirsch S.M. Antiretroviral drug resistance testing in adult HIV-1 Infection: 2008, vol. 47 (2008), Recommendations of an International AIDS Society, USA Panel CID pp. 266-285
2. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. November 3, 2008, http://aidsinfo.nih.gov.
3. Mackie N. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia. J Virol Methods 119 2 (2004) 73-78
4. Peuchant O., Thiébaut R., Capdepont S., Lavignolle-Aurillac V., Neau D., Morlat P., et al. ANRS CO3 Aquitaine Cohort. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS 31 (2008) 1417-1423 22(12)
5. Johnson J.A., Li J.F., Wei X., Lipscomb J., Irlbeck D., Craig C., et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med 29 57 (2008) e158
6. Metzner K.J., Giulieri S.G., Knoepfel S.A., Rauch P., Burgisser P., Yerly S., et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis 15 482 (2009) 239-247
7. Toni T.A., Asahchop E.L., Moisi D., Ntemgwa M., Oliveira M., Masquelier B., et al. Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection. Antimicrob Agents Chemother 53 April (4) (2009) 1670-1672
8. Shafer R.W. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 15 April (2) (2002) 247-277
9. Roquebert B., Malet I., Wirden M., Tubiana R., Valantin M.A., Simon A., et al. Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors. AIDS 20 January (2) (2006) 287-289
10. Metzner K.J., Rauch P., Walter H., Boesecke C., Zöllner B., Jessen H., et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 19 November (16) (2005) 1819-1825
11. Verhofstede C., Fransen K., Marissens D., Verhelst R., van der Groen G., Lauwers S., et al. Isolation of HIV-1 RNA from plasma: evaluation of eight different extraction methods. J Virol Methods 60 2 (1996) 155-159
12. Daar E.S. Incorporating novel virologic tests into clinical practice. Top HIV Med 15 August-September (4) (2007) 126-129
13. Ruelle J., Jnaoui K., Lefèvre I., Lamarti N., and Goubau P. Comparative evaluation of the VERSANT HIV-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the quantification of HIV-1 plasma viral load. J Clin Virol 44 4 (2009) 297-301
14. Sloma C.R., Germer J.J., Gerads T.M., Mandrekar J.N., Mitchell P.S., and Yao J.D. Comparison of the Abbott realtime human immunodeficiency virus type 1 (HIV-1) assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 test: workflow, reliability, and direct costs. J Clin Microbiol 47 4 (2009) 889-895
15. Scott L.E., Noble L.D., Moloi J., Erasmus L., Venter W.D., and Stevens W. An evaluation of the Abbott m2000 RealTime HIV-1 assay for HIV viral load monitoring in South Africa compared to existing technologies: Roche COBAS Ampliprep/COBAS Amplicor; Roche COBAS Ampliprep/COBAS TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1. J Clin Microbiol 47 7 (2009) 2209-2217
16. Schutten M., Fries E., Burghoorn-Maas C., and Niesters H.G. Evaluation of the analytical performance of the new Abbott RealTime RT-PCRs for the quantitative detection of HCV and HIV-1 RNA. J Clin Virol 40 2 (2007) 99-104
17. Scott L, Carmona S, Stevens W. The performance of the new Roche COBAS Ampliprep/COBAS TaqMan HIV-1 version 2.0 assay. J Clin Microbiol; in press
18. Gueudin M., Plantier J.C., Lemée V., Schmitt M.P., Chartier L., Bourlet T., et al. Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J Acquir Immune Defic Syndr 15 44(5) (2007) 500-505
19. Jongerius J.M., Sjerps M., Cuijpers H.T., van Drimmelen H.A., van der Poel C.L., Reesink H.W., et al. Validation of the NucliSens Extractor combined with the AmpliScreen HIV version 1.5 and HCV version 2.0 test for application in NAT minipool screening. Transfusion 42 6 (2002) 792-797
20. Germer J.J., Vandenameele J.N., Mitchell P.S., Harmsen W.S., and Yao J.D. Automated sample preparation for the TRUGENE HIV-1 genotyping kit using the MagNA pure LC instrument. Diagn Microbiol Infect Dis 49 May (1) (2004) 59-61
21. McClernon D.R., Ramsey E., and Clair M.S. Magnetic silica extraction for low-viremia human immunodeficiency virus type 1 genotyping. J Clin Microbiol 45 2 (2007) 572-574
22. Eshleman S., Crutcher G., Petrauskene O., Kunstman K., Cunningham S.P., Trevino C., et al. Sensitivity and specificity of the ViroSeq HIV-1 genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer. J Clin Microbiol 43 (2005) 813-817
23. Maes B., Schrooten Y., Snoeck J., Derdelinckx I., Van Ranst M., Vandamme A.M., et al. Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory. J Virol Methods 119 1 (2004) 45-49
24. Church J.D., Jones D., Flys T., Hoover D., Marlowe N., Chen S., et al. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn 8 September (4) (2006) 430-432
25. Stanford resistance database. http://hivdb.stanford.edu/.
26. Johnson V. Update of the drug resistance mutations in HIV-1: December 2008. International AIDS Society-USA Top HIV Med 16 5 (2008) 138-145
27. Shafer R., and Schapiro J. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 10 (2008) 67-84
28. de Mendoza C. HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines. AIDS Rev 11 January-March (1) (2009) 39-51